Document Detail

Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
MedLine Citation:
PMID:  18803678     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Recombinant human TSH (rhTSH) has become the modality of choice for radioiodine remnant ablation (RRA) in low-risk thyroid cancer patients. AIMS AND METHODS: The aims of the present prospective randomized study were to evaluate the impact of TSH stimulation procedure (hypothyroidism vs. rhTSH) on quality of life (QoL) of thyroid cancer patients undergoing RRA and to evaluate efficacy of both procedures. L-T4 was initiated in both groups after thyroidectomy. After randomization, L-T4 was discontinued in hypothyroid (hypo) group and continued in rhTSH group. A measure of 3.7 GBq of radioiodine was given to both groups. The functional assessment of chronic illness therapy-fatigue (FACIT-F) was administered from the early postoperative period to 9 months. Socio-demographic parameters, anxiety and depression scales were also evaluated (CES-D, BDI and Spielberger state-trait questionnaires). At 9 months, patients underwent an rhTSH stimulation test, diagnostic (131)I whole body scan (dxWBS) and neck ultrasonography. RESULTS: A total of 74 patients were enrolled for the study. There was a significant decrease in QoL from baseline (t0) to t1 (RRA period) in the hypothyroid group with significant differences in FACIT-F TOI (P < 10(-3)), FACT-G total score (P = 0.005) and FACIT-F total score (P = 0.003). By contrast, QoL was preserved in the rhTSH group. In the multivariate analysis, FACIT-TOI changes were only affected by the modality of TSH stimulation performed for RRA. From 3 to 9 months, changes of QoL scales and subscales were no longer statistically different in both groups of patients. Based on serum rhTSH-stimulated Tg alone (Tg < 0.8 microg/l, BRAHMS Tg Kryptor), no difference in ablation success was observed between rhTSH and hypothyroidism groups, 91.7% and 97.1%, respectively. A higher rate of persistent thyroid remnants was observed in the rhTSH arm, although in most cases uptake was < 0.1% and of no clinical significance. CONCLUSIONS: rhTSH preserves QoL of patients undergoing RRA with similar rates of ablation success compared to hypothyrodism. However, there is a wide heterogeneity in the clinical impact of hypothyroidism.
D Taïeb; F Sebag; M Cherenko; K Baumstarck-Barrau; C Fortanier; B Farman-Ara; C De Micco; J Vaillant; S Thomas; B Conte-Devolx; A Loundou; P Auquier; J F Henry; O Mundler
Related Documents :
18959638 - Feasibility study of day case thyroidectomy.
16143188 - Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of ra...
1973768 - Comparison of placebo with l-thyroxine alone or with carbimazole for treatment of spora...
17549318 - Administration of additional inactive iodide during radioiodine therapy for graves' dis...
12719078 - A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intr...
2302518 - Simple closure of perforated duodenal ulcer: a prospective evaluation of a conservative...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-09-18
Journal Detail:
Title:  Clinical endocrinology     Volume:  71     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-20     Completed Date:  2009-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  115-23     Citation Subset:  IM    
Service Central de Biophysique et de Médecine Nucléaire, Centre Hospitalo-Universitaire de la Timone, Marseille Cedex 5, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Iodine Radioisotopes / therapeutic use*
Middle Aged
Prospective Studies
Quality of Life*
Recombinant Proteins / therapeutic use
Thyroid Neoplasms / drug therapy*
Thyrotropin / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Recombinant Proteins; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Placental production and maternal serum and urine levels of inhibin A and activin A are modified by ...
Next Document:  Leptin concentration indexed to fat mass is increased in untreated anorexia nervosa (AN) patients.